2. Immunology/Inflammation
  3. Interleukin Related
  4. QX008N

QX008N is a humanized IgG1 monoclonal antibody and also a TSLP inhibitor with a KD value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma.

For research use only. We do not sell to patients.

QX008N

QX008N Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

QX008N Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

QX008N is a humanized IgG1 monoclonal antibody and also a TSLP inhibitor with a KD value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma[1][2].

Species Reactivity

Human
IC50 & Target[1]

IL7R

 

In Vitro

QX008N binds human TSLP with a high affinity (Kd = 0.0175 nM) that is superior to the Tezepelumab (HY-P99366A) analog[1].
QX008N (2 μg/mL initial concentration, 1:5 gradient dilutions) specifically binds human, cynomolgus monkey, and rhesus macaque TSLP[1].
QX008N potently inhibits the interaction between human TSLP and the TSLPR-IL-7Rα complex[1].
QX008N (2 μg/mL initial concentration, 1:3 gradient dilutions) potently neutralizes TSLP-induced JAK/STAT signaling in SW756-STAT5-Luciferase cells exposed to recombinant human, natural human, or recombinant cynomolgus monkey TSLP[1].
QX008N (10 concentration points via 1:5 gradient dilutions) potently inhibits human TSLP-induced CCL17 secretion in human PBMCs (IC50 = 9.836 ng/mL) and whole blood (IC50 = 1.599 ng/mL), and CCL22 secretion in human PBMCs, with activity superior to the Tezepelumab analog[1].
QX008N, when combined with anti-IL-4R antibody Oturkibart (HY-P991152), potently inhibits CCL17 production in human PBMCs stimulated with TSLP, IL-4, IL-13, and IL-33, achieving 95.5% inhibition that exceeds the additive effect of monotherapies[1].
QX008N (6 day incubation), when combined with anti-IL-4R antibody QX005N, enhances inhibition of OVA-induced CCL17, IL-5, and CCL26 production in a ternary culture model of MRC-5 fibroblasts, A549 epithelial cells, and human PBMCs, compared to QX008N monotherapy[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

QX008N Related Antibodies
In Vivo

QX008N (10-50 mg/kg; once weekly; 6 doses; subcutaneous injection) dose-dependently improves lung function, reduces peripheral blood and bronchoalveolar lavage fluid inflammatory markers, and decreases eosinophil infiltration in a cynomolgus monkey asthma model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Cynomolgus monkey (male, 3-6 years, 2.5-7.0 kg, sensitized via intraperitoneal injection of Ascaris suis extract mixed with Al(OH)3 adjuvant at weeks 1, 2, and 3, followed by nebulized allergen challenge at weeks 4-7)[1]
Dosage: 10 mg/kg; 50 mg/kg
Administration: once weekly; 6 doses; subcutaneous injection
Result: Decreased percentage change in airway resistance by 25% and increased percentage change in lung dynamic compliance by 20% at one week after three 10 mg/kg doses.
Reduced peripheral blood specific IgE by ~38% after three 10 mg/kg doses and TSLP by ~42% after six 10 mg/kg doses.
Decreased percentage change in airway resistance by 42.4% and increased percentage change in lung dynamic compliance by 30% at one week after first 50 mg/kg dose.
Reduced peripheral blood TSLP by ~66% and specific IgE by ~62% after first 50 mg/kg dose.
Lowered TSLP levels, eosinophil counts and eosinophil percentage in bronchoalveolar lavage fluid at 10 mg/kg and 50 mg/kg.
Attenuated eosinophil infiltration in lung tissue at 10 mg/kg and 50 mg/kg.
Reached plasma concentration of 336.3 μg/mL after first 50 mg/kg dose.
Gene ID

85480  [NCBI]

Accession

Q969D9-1
Target

TSLP
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

QX008N Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

QX008NInterleukin RelatedILIgEhuman PBMCsasthmaJAK/STAT signalingcynomolgus monkeySW756-STAT5-Luciferase cellssevere asthmaeosinophilTSLPR-IL-7RαTSLPInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
QX008N
Cat. No.:
HY-P992447
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.